Oxford Biomedica (UK) Limited

Other

Ucl Business Plc

Cancer Research Campaign Technology Limited

The Institute of Cancer Research: Royal Cancer Hospital

Genetic Therapy, Inc.

Yasuhiro Takeuchi

Robin Anthony Weiss

Mary Collins

Kyriacos Andreou Mitrophanous

Francois-Loic Cosset

Yasuhiro Ikeda

Michael Pensiero

Mary Katharine Collins

Francois-Lois Cosset

Sean Knight

Mary Katherine Collins

Mary K L Collins

Lentiviral packaging cells and methods for producing the same are provided herein. Specifically, lentiviral packaging cells capable of producing lentiviral vector suitable for use in clinical trials are provided. Methods for producing lentiviral packaging cells capable of producing lentiviral vector suitable for use in clinical trials are described.

Materials and methods relating to packaging cell lines

Provided herein is a retroviral vector comprising, and capable of expressing, a nucleotide of interest (NOI), wherein the NOI encodes an RNA or protein which is harmful to a cell.

Retroviral vector

Retroviral vectors which are resistant to inactivation by human serum. The retroviral vectors are produced in a cell line which is resistant to lysis by human serum, such cell lines including the HOS, Mv-1-Lu, HT1080, TE671, and human 293 cell lines, as well as cell lines derived therefrom. Such retroviral vectors are especially useful as in vivo gene delivery vehicles.

Retroviral vectors produced by producer cell lines resistant to lysis by human serum

Expression systems

Retroviral which are resistant to inactivation by human serum. The retroviral vectors are produced in a cell line which is resistant to lysis by human serum, such cell lines including the HOS, Mv-1-Lu, HT1080, TE671, and human 293 cell lines, as well as cell lines derived therefrom. Such retroviral vectors are especially useful as in vivo gene delivery vehicles.

Retroviral vectors produced by producer cell lines resistant to lysis by

Growing community of inventors

London, United Kingdom

Yasuhiro Takeuchi